GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » Beta

Merus Labs International (Merus Labs International) Beta : N/A (As of May. 07, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-07), Merus Labs International's Beta is Not available.


Merus Labs International Beta Historical Data

The historical data trend for Merus Labs International's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International Beta Chart

Merus Labs International Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 0.88 1.23 2.26 2.34

Merus Labs International Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 2.51 2.34 2.45 2.21

Competitive Comparison of Merus Labs International's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus Labs International's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's Beta distribution charts can be found below:

* The bar in red indicates where Merus Labs International's Beta falls into.



Merus Labs International Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Merus Labs International  (NAS:MSLI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Merus Labs International Beta Related Terms

Thank you for viewing the detailed overview of Merus Labs International's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus Labs International (Merus Labs International) Business Description

Traded in Other Exchanges
N/A
Address
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines